Thus, IGF2BP2 contributes to CRC proliferation.[44] Numerous studies have shown that IGF2BP3 is highly expressed in CRC tissues and is associated with adverse clinical outcomes.[45–49] Recently, Xu et al first revealed the oncogenetic role of IGF2BP3 in CRC. This evidence concerns the gene IGF2BP2 and colorectal carcinoma.